Clinical trials: design, endpoints and interpretation of outcomes
- PMID: 34997213
- DOI: 10.1038/s41409-021-01542-0
Clinical trials: design, endpoints and interpretation of outcomes
References
-
- Zheng C, Dai R, Gale R, Zhang M. Causal inference in randomized clinical trials. Bone Marrow Transpl. 2019;55:4–8. - DOI
-
- Jabbour J, Manana B, Zahreddine A, Al-Shaar L, Bazarbachi A, Blaise D, et al. Vitamins and minerals intake adequacy in hematopoietic stem cell transplant: results of a randomized controlled trial. Bone Marrow Transpl. 2021;56:1106–15. - DOI
-
- Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–53. - DOI
-
- DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29. - DOI
-
- Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–47. - DOI
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources